SCHEMBL149474

SCHEMBL149474

C[Si](C)(C)CCONC(=O)O

nearest known ligand 0.33

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.33
CYP2D6 P10635 1/20 0.30
CYP2C19 P33261 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27797987 0.73
SCHEMBL4809579 0.73 CYP2D6 (0.34) CYP2D6CYP2C19
SCHEMBL3509561 0.71
SCHEMBL3512280 0.70
SCHEMBL14798711 0.70
SCHEMBL1495274 0.70
SCHEMBL12487443 0.70 ACHE (0.35) CYP2D6
Hydrochloric Acid SCHEMBL8220484 0.69
Hydrochloric Acid SCHEMBL20450562 0.69
SCHEMBL154678 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011103435-A2 METHODS FOR FORMING PROTECTED ORGANOBORONIC ACIDS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2011-08-25 WO claimed
CN-114466849-B N-substituted-3, 4- (fused 5-ring) -5-phenyl-pyrrolidin-2-one compounds as ISOQC and/or inhibitors of QC enzymes 欣尼克免疫有限公司 2024-07-12 CN disclosed
US-20240000947-A1 POLYPEPTIDE MODIFICATION AND CONJUGATION METHODS Encodia, Inc. (US) 2024-01-04 US disclosed
US-20230193248-A1 METHODS FOR PROTEIN IDENTIFICATION BASED ON ENCODING REACTIONS Encodia, Inc. (US) 2023-06-22 US disclosed
CN-114466849-A N-substituted-3, 4- (fused 5-ring) -5-phenyl-pyrrolidin-2-one compounds as inhibitors of ISOQC and/or QC enzymes 欣尼克免疫有限公司 2022-05-10 CN disclosed
EP-2885302-B1 PROCESS FOR THE PREPARATION OF DIPEPTIDYLPEPTIDASE INHIBITORS GLENMARK PHARMACEUTICALS LTD (IN) 2018-03-07 EP disclosed
US-9908900-B2 Methods for forming protected organoboronic acids THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2018-03-06 US disclosed
US-9845317-B2 Slow release of organoboronic acids in cross-coupling reactions THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2017-12-19 US disclosed
US-9732102-B2 System for controlling the reactivity of boronic acids THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2017-08-15 US disclosed
US-9593119-B2 Process for the preparation of dipeptidylpeptidase inhibitors GLENMARK PHARMACEUTICALS LIMITED (IN) 2017-03-14 US disclosed
US-8557980-B2 Methods for forming protected organoboronic acids THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2013-10-15 US disclosed
US-8338601-B2 Slow release of organoboronic acids in cross-coupling reactions BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2012-12-25 US disclosed
US-8318983-B2 System for controlling the reactivity of boronic acids THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2012-11-27 US disclosed
US-20120059184-A1 System for Controlling the Reactivity of Boronic Acids THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2012-03-08 US disclosed
US-8013203-B2 System for controlling the reactivity of boronic acids THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2011-09-06 US disclosed
WO-2011103435-A2 METHODS FOR FORMING PROTECTED ORGANOBORONIC ACIDS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2011-08-25 WO disclosed
US-20110201806-A1 Methods for Forming Protected Organoboronic Acids NATIONAL SCIENCE FOUNDATION 2011-08-18 US disclosed
US-20100121062-A1 Slow Release of Organoboronic Acids in Cross-Coupling Reactions THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2010-05-13 US disclosed
WO-2010036921-A2 SLOW RELEASE OF ORGANOBORONIC ACIDS IN CROSS-COUPLING REACTIONS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2010-04-01 WO disclosed
US-20090030238-A1 SYSTEM FOR CONTROLLING THE REACTIVITY OF BORONIC ACIDS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS 2009-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100121062-A1 Slow Release of Organoboronic Acids in Cross-Coupling Reactions BRS3, CD79B, GRB2 KMT2A 3510/4885CYP2D6 447/4885CYP2C19 1458/4885
US-20110201806-A1 Methods for Forming Protected Organoboronic Acids NISCH, TBCB, DBN1 KMT2A 3279/4885CYP2D6 312/4885CYP2C19 2136/4885
US-20120059184-A1 System for Controlling the Reactivity of Boronic Acids ORC3, BRS3, OSBPL3 KMT2A 3075/4885CYP2D6 1333/4885CYP2C19 2867/4885
US-20240000947-A1 POLYPEPTIDE MODIFICATION AND CONJUGATION METHODS PHAX, PTMS, DNPEP KMT2A 571/4885CYP2D6 2748/4885CYP2C19 4227/4885
US-20090030238-A1 SYSTEM FOR CONTROLLING THE REACTIVITY OF BORONIC ACIDS ORC3, BRS3, OSBPL3 KMT2A 3075/4885CYP2D6 1333/4885CYP2C19 2867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.